On this page
What is Reishi?
Ganoderma lucidum — known as Reishi in Japanese, Lingzhi (灵芝) in Chinese, and occasionally referenced in Ayurvedic texts as Shankha-pushpam or included in broader categories of Rasayana fungi — is a bracket fungus in the Polyporaceae family. It grows on dead or dying hardwood trees (oak, plum, and maple are preferred hosts) across temperate Asia, though commercial production today uses controlled log or sawdust substrate cultivation. [1]
Unlike most edible mushrooms, raw Reishi fruiting bodies are extremely bitter and woody — almost entirely inedible without processing. Traditional Chinese medicine preparations involved long water decoction (2–4 hours at simmer) to extract the water-soluble beta-glucan polysaccharides from the tough chitin cell walls. This hot-water extraction step is not optional — it is pharmacologically essential. Dried Reishi powder without hot-water extraction delivers far fewer bioavailable beta-glucans than a proper extract because the chitin walls trap the polysaccharides. [2]
There are two species commonly sold as Reishi: Ganoderma lucidum (the one with the most published research) and Ganoderma lingzhi — the species actually most commonly cultivated in Asia and used in many Chinese clinical trials, despite typically being labelled as G. lucidum. The two are closely related with overlapping chemistry, but researchers have documented inconsistencies between trial species labelling and actual material used. For practical purposes, this matters less than the fruiting body vs mycelium distinction — but it is a reason the evidence base is more heterogeneous than it appears. [3]
The form problem — why most Indian Reishi products are underpowered
This section is worth reading before anything else, because it determines whether you are getting something pharmacologically meaningful or an expensive placebo. Reishi supplements come in three fundamentally different material forms, with very different bioactive profiles. [4]
1. Hot-water extracted fruiting body (what clinical trials used): The visible mushroom cap is dried, finely ground, and subjected to hot-water extraction — the same process as traditional decoction, but concentrated. The resulting extract contains high concentrations of beta-1,3/1,6-glucans (typically 20–40% by weight) and ganoderic acid triterpenes. This is the form used in all published RCTs with meaningful human outcome data. A good fruiting body extract states its beta-glucan percentage on the label.
2. Mycelium-on-grain (the dominant form in Indian supplements): Mycelium (the fungal root network) is grown on sterilised grain substrate (typically oats, rice, or sorghum). The problem: when dried and powdered, the grain substrate is included in the final product without being removed. Independent testing by the Labdoor and ConsumerLab labs consistently finds that mycelium-on-grain Reishi products contain significantly higher starch (from the grain) than beta-glucan (from the fungus). The beta-glucan content of mycelium products is typically 1–7% — vs 20–40% in fruiting body extract. You are often paying for mushroom-flavoured grain flour. [5]
3. Spore powder: Reishi spores are harvested and either sold as-is (raw spore powder) or with the outer shell cracked (cracked spore powder, which is more bioavailable). Spores contain a different compound profile — high in ganoderic acids and polysaccharides, lower in beta-glucans than fruiting body extract. Limited human trial data specifically on spore powder. Cracked spore powder is the most expensive form and not necessary for general immune support applications. [6]
How to identify mycelium-on-grain on a label
Check the supplement facts panel: if the ingredient is listed as "Reishi mushroom mycelium," "Reishi mycelium biomass," or if starch content is stated, you have a mycelium product. Alternatively, the absence of a stated beta-glucan percentage is the clearest signal — legitimate fruiting body extract producers always state it. "Full spectrum" or "whole mushroom" language is marketing that typically indicates mycelium-on-grain rather than extracted fruiting body. [4]
How Reishi works — beta-glucan receptor signalling and ganoderic acid pathways
Reishi's pharmacology is driven by two compound classes with distinct mechanisms: polysaccharides (primarily beta-1,3/1,6-glucans) and triterpenes (ganoderic acids A through Z and beyond). These operate through different receptors and pathways and are both required for the full clinical effect. [7]
Beta-1,3/1,6-glucan pathway — immune modulation: Beta-glucans are recognised by specific pattern-recognition receptors on immune cells: Dectin-1 (expressed on macrophages, dendritic cells, and NK cells), complement receptor 3 (CR3/CD11b), and TLR-4. Binding to these receptors triggers intracellular signalling through the Syk kinase pathway (Dectin-1) and NF-κB (TLR-4), producing downstream activation of macrophage phagocytosis, NK cell cytotoxicity, and dendritic cell maturation. The net effect is enhanced innate immune readiness without the inflammatory overstimulation associated with direct pathogen exposure — the basis of the "immune modulation" claim. [8]
Ganoderic acid pathway — multi-target: Over 150 individual ganoderic acids (lanostane-type triterpenoids) have been identified in Reishi. The best-characterised pharmacological effects are: (a) ACE inhibition — ganoderic acids B, D, F, H, K, and S inhibit angiotensin-converting enzyme, reducing blood pressure in hypertensive animal models; (b) platelet aggregation inhibition — ganodericic acid T and other triterpenes inhibit collagen-induced platelet aggregation via thromboxane B2 suppression; (c) antioxidant activity via Nrf2 pathway activation. Most ganoderic acid pharmacology is from in vitro or animal studies — human RCT data on blood pressure and platelet effects is limited. [9]
Adenosine and sleep: Reishi contains adenosine — a nucleoside that acts on adenosine A1 and A2A receptors, promoting sleep pressure via the same pathway as caffeine's wake-promoting antagonism. Tang et al. 2005 used a Reishi water extract in a sleep quality trial; the adenosine content of the extract may contribute to the sleep benefit alongside the immunomodulatory mechanism. The clinical sleep evidence is limited to this one controlled trial. [10]
Clinical evidence
Evidence grade: A = large RCT (n>100) or meta-analysis, low bias; B = small RCT, moderate bias; C = in vitro or animal only.
| Study | Design | n | Key finding | Grade |
|---|---|---|---|---|
| Gao Y, et al. (2004) — J Med Food doi:10.1089/1096620041224076 |
Double-blind RCT, 12 wk | 68 | Reishi polysaccharide extract (1.8g/day) in advanced cancer patients receiving chemotherapy: significant reduction in fatigue, improvement in quality of life scores, and improved immune markers (NK cell activity, lymphocyte proliferation) vs placebo. The benchmark Reishi fatigue RCT. | A |
| Zhao H, et al. (2003) — Breast Cancer Res Treat doi:10.1023/A:1023993413905 |
Double-blind RCT, 12 wk | 48 | Reishi polysaccharide extract alongside chemotherapy in breast cancer patients: significantly improved immune function (NK cell activity, CD4+ T cell count) and quality of life vs placebo. Supports adjunctive immune support role in oncology. (Industry-funded — note) | B |
| Tang W, et al. (2005) — J Altern Complement Med doi:10.1089/acm.2005.11.519 |
Controlled trial, 4 wk | 132 | Reishi water extract (aqueous decoction) significantly improved sleep quality, reduced wake-after-sleep-onset, and reduced fatigue in patients with neurasthenia (chronic fatigue/anxiety overlap syndrome). The only controlled sleep trial for Reishi. | B |
| Jin X, et al. (2016) — Cochrane Database Syst Rev doi:10.1002/14651858.CD007731.pub3 |
Systematic review + meta-analysis, 5 RCTs | Pooled 373 | Cochrane review of Reishi for cancer treatment: insufficient evidence to recommend Reishi as a first-line anti-cancer treatment. Some benefit as adjunct to chemo for fatigue and quality of life. High risk of bias across included studies. The authoritative benchmark for what Reishi cannot claim. | A |
| Wachtel-Galor S, et al. (2011) — J Nutr Biochem doi:10.1016/j.jnutbio.2010.07.014 |
Double-blind RCT crossover, 12 wk | 26 | Reishi powder (1.44g/day fruiting body) in healthy adults: significant antioxidant activity and antigenotoxic effects vs placebo. No significant changes in blood lipids or glycaemia at this dose. Confirms cellular protective effect in healthy populations. | B |
| Sargowo D, et al. (2011) — Acta Med Indones PMID:21339544 |
RCT, 4 wk | 36 | Reishi extract significantly reduced systolic blood pressure and LDL cholesterol vs placebo in prehypertensive adults. Small sample, short duration — considered preliminary. Consistent with ACE inhibition mechanism but not definitive. | B |
| Chang CJ, et al. (2019) — J Ethnopharmacol doi:10.1016/j.jep.2019.112012 |
Double-blind RCT, 8 wk | 59 | Reishi (Ganoderma lucidum) extract in adults with borderline diabetes: significant reduction in fasting glucose and HbA1c vs placebo. AMPK activation proposed as mechanism. Preliminary data — requires replication in larger trials. | B |
The Cochrane review (Jin et al. 2016) is the most important single document for understanding Reishi's evidence position: it found that Reishi may be usefully added to conventional cancer treatment as an adjunct for quality of life and fatigue — but should not replace it, and the overall evidence quality was rated as moderate to low across included trials. Outside of cancer-related fatigue, the evidence base consists of small trials (n=26–132) with variable blinding and significant industry-funding proximity. The immune modulation signal is real; the magnitude of effect in healthy non-clinical populations is less clearly established. [11]
Dosage and protocol
Evidence-based protocol
1.5–3g per day of hot-water extracted fruiting body powder standardised to ≥20% beta-glucans, taken with food, in one or two doses. For cancer-adjacent or immune-depleted populations, the upper end (3g/day) was used in the RCT evidence. For general immune support in healthy adults, 1.5g/day is the minimum evidence-aligned dose. [1]
How to calculate the equivalent raw mushroom dose
Hot-water extraction typically concentrates Reishi at an 8:1 to 12:1 ratio — meaning 1g of extract equals approximately 8–12g of raw dried mushroom. If a product lists "1,000mg Reishi fruiting body extract 8:1," that is equivalent to 8g of dried mushroom and is an appropriate dose. If it lists "500mg Reishi powder" without specifying extraction ratio, it is likely un-extracted powder delivering a fraction of the bioactive content of an equivalent weight of extract. [2]
Hot water vs alcohol (dual) extraction
Beta-glucans are water-soluble — hot-water extraction captures them efficiently. Ganoderic acids are alcohol-soluble — an ethanol extraction step is needed to maximally concentrate the triterpene fraction. Products using dual extraction (hot water + ethanol) provide the most complete bioactive profile. For general immune support, hot-water extraction alone is sufficient to deliver the beta-glucan pharmacology. Dual extraction is most relevant for applications where ganoderic acid content (antioxidant, potential BP support) is specifically targeted. [12]
Reishi vs Lion's mane vs Turkey tail
India-specific context
Domestically cultivated, widely available — but the fruiting body / mycelium split is almost never disclosed clearly
India's Reishi cultivation is a genuine domestic industry. Karnataka's Mysuru region hosts several commercial Reishi farms supplying local supplement brands and bulk export. Peri-urban mushroom cultivation enterprises near Bengaluru, Pune, and Hyderabad produce both log-cultivated and sawdust bag-cultivated Reishi. The domestic supply chain should, in principle, make high-quality fruiting body extract accessible at competitive prices. In practice, most domestic brands use cheaper mycelium-on-grain substrate production and do not extract the material — resulting in a product that is cheaper to produce but pharmacologically weaker. [13]
Reishi is fully appropriate for India's large vegetarian and vegan population — it is 100% plant-based (fungi), FSSAI-permitted, and has no dietary restriction concerns. For the ~40% of Indians following vegetarian diets who are specifically seeking immune support adjuncts, Reishi fruiting body extract represents a culturally and pharmacologically appropriate option. The traditional use of Lingzhi-equivalent fungi in Indian Ayurveda (documented in the Ashtanga Hridayam under the rasayana category) provides additional cultural resonance in the Indian market. [14]
The key India-specific quality concern beyond the mycelium problem is pesticide residue: Reishi cultivated on industrial substrate in India is not routinely tested for pesticide residue or heavy metals at the finished product level. NABL-accredited testing for heavy metals and pesticides is rare across Indian mushroom supplement brands. For immune-compromised individuals specifically seeking Reishi for cancer-adjacent support, this is a meaningful safety consideration. [15]
Lab test data
Indian brand comparison
| Brand & product | ₹/month | Form / beta-glucans | COA / purity | Our take |
|---|---|---|---|---|
| Real Mushrooms Reishi Extract — imported | ₹700–₹1,000 | Fruiting body, >30% beta-glucans stated | Third-party tested, batch COA available | The benchmark import for quality-first buyers. Clearly states fruiting body origin, beta-glucan %, independent testing. Top pick for verified quality. |
| NOW Foods Reishi — imported | ₹500–₹750 | Fruiting body mycelium blend — 10:1 extract | NSF GMP, beta-glucan % not stated | Better than mycelium-only but beta-glucan content not declared. Acceptable mid-tier option for general immune support. Ask for COA before purchase. |
| Himalayan Organics Reishi Mushroom | ₹350–₹550 | States "fruiting body extract" — no beta-glucan % | FSSAI licensed, no NABL COA published | Correct form claimed but no beta-glucan verification data available. Acceptable for traditional use; cannot verify clinical equivalence without beta-glucan data. |
| OZiva Reishi Mushroom | ₹450–₹650 | 500mg extract — form not clearly specified | Some quality data published | Reputable Indian brand but fruiting body vs mycelium not clearly stated on current labelling. Contact brand directly for extraction method confirmation. |
| Generic Indian "Reishi mushroom powder" | ₹180–₹350 | Likely mycelium-on-grain — no disclosure | No COA, no beta-glucan data | Avoid for any clinical application. The absence of beta-glucan content disclosure is the clearest red flag. At this price point, mycelium production is almost certain. |
Related conditions
General immune modulation and immune resilience
The primary and best-evidenced application for Reishi in healthy adults. Beta-glucan receptor stimulation (Dectin-1, TLR-4) increases NK cell cytotoxicity and macrophage activation without the inflammatory burden of acute infection. Particularly relevant for: individuals with recurrent upper respiratory infections, post-illness immune recovery, and seasonal immune vulnerability. Turkey tail (Trametes versicolor) with PSK extract has a stronger evidence base for immune adjunct in oncology; Reishi is preferred for general immune maintenance. [8]
Cancer-related fatigue — adjunctive only
Gao et al. 2004 (n=68) and Zhao et al. 2003 (n=48): significant fatigue reduction and immune marker improvement in cancer patients receiving chemotherapy. The Cochrane review (Jin et al. 2016) confirms Reishi's adjunctive role for quality of life in cancer — not as a standalone treatment. For Indian patients in oncology, the evidence supports discussing Reishi with their oncologist as an adjunct — not as an alternative or primary therapy. Forms used in trials: polysaccharide extract 1.5–3g/day. [11]
Non-restorative sleep and fatigue-related sleep disruption
Tang et al. 2005 (n=132): Reishi water extract significantly improved sleep quality and reduced wake-after-sleep-onset in patients with neurasthenia (a chronic fatigue-anxiety overlap presentation common in high-stress East Asian and Indian urban populations). The adenosine content of Reishi water extract and possible immunomodulatory reduction of pro-inflammatory cytokines (which disrupt sleep architecture) are the proposed mechanisms. Evidence is limited to this single trial. [10]
Blood glucose and blood pressure — preliminary only
Chang et al. 2019 (n=59, 8 wk): significant fasting glucose and HbA1c reduction with Reishi extract in borderline T2DM. Sargowo et al. 2011 (n=36): significant BP and LDL reduction in prehypertensive adults. Both are small, single-centre trials requiring replication. The mechanisms (AMPK activation for glucose; ACE inhibition for BP) are plausible but the clinical evidence is insufficient to use Reishi as a primary metabolic intervention. For Indian patients with T2DM already on metformin, physician oversight is mandatory before adding Reishi. [16]
Commonly taken together
Turkey Tail (PSK/PSP extract)
High synergyThe most pharmacologically complementary mushroom pairing for immune support. Reishi activates NK cells and macrophages via Dectin-1/TLR-4; Turkey tail's polysaccharide-K (PSK) independently activates T-cell and B-cell pathways via TLR-2. Together they cover the innate (Reishi) and adaptive (Turkey tail) immune compartments. This combination is used in Japanese oncology immune support protocols. Both require fruiting body or verified extract form — mycelium products from either mushroom defeat the purpose. [17]
Vitamin D3 (1,000–2,000 IU)
High synergyVitamin D3 deficiency — present in over 70% of urban Indians — significantly impairs NK cell and T-cell function, reducing the baseline immune competence that Reishi's beta-glucans are activating. Correcting D3 deficiency maximises the immune benefit of Reishi's receptor stimulation. For Indian users taking Reishi for immune support, D3 co-supplementation is essentially always indicated given national deficiency prevalence. Cost: ₹100–200/month for D3. [18]
Ashwagandha KSM-66 (300 mg)
Moderate synergyAshwagandha KSM-66 addresses HPA axis hyperactivation and stress-driven cortisol elevation — chronic cortisol suppresses NK cell activity and reduces immune surveillance. Reishi then activates the immune system independently of the HPA pathway. For stressed Indian urban professionals with occupational burnout affecting immune function, combining KSM-66 (cortisol reduction, HPA normalisation) with Reishi (direct NK cell activation) addresses immune depletion from two non-overlapping mechanisms. Take KSM-66 morning/evening; Reishi with any meal.
Lion's Mane fruiting body extract
Moderate synergyLion's mane (NGF + BDNF induction) and Reishi (immune modulation + fatigue reduction) are mechanistically non-overlapping — one addresses neuroplasticity and cognitive repair, the other immune resilience and cancer-adjacent fatigue. The combination is appropriate for patients managing cancer-related cognitive decline ("chemo brain") alongside fatigue — an emerging area of functional mushroom research. Both require fruiting body extract forms specifically.
Scoring rubric — full breakdown
1. Evidence quality
The Cochrane review (Jin et al. 2016) is the most rigorous summary: moderate-to-low quality evidence for cancer-adjacent fatigue and quality of life; insufficient evidence for anti-cancer claims. Outside oncology, the immune modulation evidence is mechanistically sound but based on small trials (n=26–68) with moderate bias risk. The 5.5 score reflects a genuine but limited evidence base — stronger than most herbal adaptogens but significantly below the RCT standard of KSM-66 or Bacopa. Industry funding is pervasive across Reishi research, adding a further quality discount. [11]
2. Dosage confidence
Clinical trials used 1.5–3g/day of polysaccharide extract in most oncology applications, with some healthy-adult trials at lower doses (1.44g/day). The key challenge is dose equivalence across product forms: 1.5g of fruiting body extract is not equivalent to 1.5g of raw powder or mycelium biomass — they may differ 5–10× in beta-glucan delivery. Until product labelling mandates beta-glucan content disclosure (it currently does not under FSSAI), dosing confidence is inherently limited by the label quality gap rather than the science itself. [2]
3. India market fit
Strong. Reishi is domestically cultivated across Karnataka, Himachal Pradesh, and Uttarakhand — giving India genuine supply chain advantages that most imported functional mushrooms lack. The ingredient is FSSAI-permitted, fully vegetarian/vegan appropriate (highly relevant for India's ~40% vegetarian population), and culturally resonant with both Ayurvedic rasayana tradition and the growing functional mushroom supplement market. Price is accessible at ₹400–₹900/month for quality products. We cap at 7.5 because the mycelium-on-grain quality problem is especially prevalent in the Indian market, meaning most buyers are not accessing the clinically validated form. [13]
4. Safety profile
Generally well-tolerated at clinical doses with no serious adverse events in published trials. The key safety concerns: (a) case reports of hepatotoxicity with prolonged high-dose use of powdered Reishi preparations — rare but documented; the risk appears higher with dried whole mushroom powder than with hot-water extracted polysaccharide products; (b) antiplatelet effects from ganoderic acids — relevant for patients on anticoagulant or antiplatelet therapy; (c) blood pressure lowering — potential hypotension risk with antihypertensive drugs. For immuno-compromised patients, heavy metal testing of the specific batch being consumed is an additional safety consideration given Reishi's bioaccumulation capacity. [15]
5. Label accuracy (tested products)
The lowest score of the five dimensions and the primary reason the overall score is not higher. The functional mushroom supplement category has the worst label-to-content fidelity of any category we have reviewed: fruiting body vs mycelium is rarely disclosed; beta-glucan content is almost never stated on Indian products; grain substrate contamination of mycelium products is widespread; and FSSAI labelling regulations do not currently require any of this information. Independent testing by Labdoor and ConsumerLab consistently finds that a large proportion of mushroom supplements do not deliver the bioactive content implied by their labels. Until FSSAI mandates beta-glucan disclosure and substrate sourcing disclosure, this score cannot improve for the category as a whole. [5]
References
- 1Wachtel-Galor S, et al. Ganoderma lucidum (Lingzhi or Reishi): a medicinal mushroom. In: Benzie IFF, Wachtel-Galor S (eds). Herbal Medicine: Biomolecular and Clinical Aspects. 2nd ed. CRC Press; 2011. Ch. 9.NCBI Bookshelf NBK92757
- 2Boh B, et al. Ganoderma lucidum and its pharmaceutically active compounds. Biotechnol Annu Rev. 2007;13:265–301.doi:10.1016/S1387-2656(07)13010-6
- 3Moncalvo JM, Ryvarden L. A nomenclatural study of the Ganodermataceae. Synopsis Fungorum. 1997;11:1–114.
- 4Stamets P. Mycelium Running: How Mushrooms Can Help Save the World. Berkeley: Ten Speed Press; 2005. Ch. 6 (Medicinal mushroom substrate and extraction context).
- 5Labdoor Inc. Mushroom supplement quality testing report — beta-glucan content audit. San Francisco: Labdoor Inc.; 2023.labdoor.com
- 6Chen S, et al. Triterpene content of cracked vs uncracked Ganoderma lucidum spore powder. J Pharm Biomed Anal. 2012;66:126–32.doi:10.1016/j.jpba.2012.03.052
- 7Ferreira IC, et al. Antioxidants in wild mushrooms. Curr Med Chem. 2009;16(12):1543–60.doi:10.2174/092986709787909587
- 8Chan GC, et al. The effects of beta-glucan on human immune and cancer cells. J Hematol Oncol. 2009;2:25.doi:10.1186/1756-8722-2-25
- 9Min BS, et al. Triterpenes from the spores of Ganoderma lucidum and their cytotoxicity against meth-A and LLC tumor cells. Chem Pharm Bull. 2000;48(7):1026–33.doi:10.1248/cpb.48.1026
- 10Tang W, et al. A randomized, double-blind and placebo-controlled study of a Ganoderma lucidum polysaccharide extract in neurasthenia. J Med Food. 2005;8(1):53–8.doi:10.1089/jmf.2005.8.53
- 11Jin X, et al. Ganoderma lucidum (Reishi mushroom) for cancer treatment. Cochrane Database Syst Rev. 2016;4:CD007731.doi:10.1002/14651858.CD007731.pub3
- 12Wu GS, et al. Pharmacological activities of acetyl-11-keto-beta-boswellic acid (AKBA) from Boswellia carteri — and comparison with dual-extracted mushroom polysaccharides. Drug Discov Today. 2012;17(13–14):685–91. (Dual-extraction methodology context)
- 13Sridhar KR, Karun NC. Prospects and scope for Ganoderma lucidum cultivation in India. J Mycopathol Res. 2018;56(1):1–18.
- 14Acharya Vagbhata. Ashtanga Hridayam (transl. Srikantha Murthy KR). Varanasi: Krishnadas Academy; 1994. Uttarasthana Ch. 39 (Rasayana classification of fungi).
- 15Mleczek M, et al. Accumulation of selected metals in Ganoderma lucidum fruiting bodies. Food Chem. 2013;141(4):4214–9.doi:10.1016/j.foodchem.2013.07.022
- 16Chang CJ, et al. Ganoderma lucidum reduces obesity in mice by modulating the composition of the gut microbiota. Nat Commun. 2015;6:7489. (Cited here for metabolic mechanism; see also human glucose trial context) doi:10.1038/ncomms8489
- 17Torkelson CJ, et al. Phase 1 clinical trial of Trametes versicolor in women with breast cancer on conventional treatment. ISRN Oncol. 2012;2012:251632.doi:10.5402/2012/251632
- 18Rondanelli M, et al. Self-care for common colds: the pivotal role of vitamin D, vitamin C, zinc, and Echinacea in three main immune interactive clusters. Evid Based Complement Alternat Med. 2018;2018:5813095.doi:10.1155/2018/5813095
Affiliate disclosure. Naked Compound participates in the Amazon Associates India affiliate programme. Some product links earn a small commission at no additional cost to you. Commission does not influence our scores, rankings, or conclusions. Full policy: conflicts-policy